Charles Schwab Investment Management Inc Entrada Therapeutics, Inc. Transaction History
Charles Schwab Investment Management Inc
- $515 Billion
- Q3 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Entrada Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 185,984 shares of TRDA stock, worth $3.7 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
185,984
Previous 162,341
14.56%
Holding current value
$3.7 Million
Previous $2.31 Million
28.53%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding TRDA
# of Institutions
101Shares Held
28.1MCall Options Held
34.5KPut Options Held
16.4K-
Baker Bros. Advisors LP New York, NY4.87MShares$96.8 Million0.83% of portfolio
-
Mpm Asset Management LLC Cambridge, MA4.43MShares$88 Million48.7% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA4.41MShares$87.7 Million28.09% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.05MShares$60.7 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X01.71MShares$34 Million0.01% of portfolio
About Entrada Therapeutics, Inc.
- Ticker TRDA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 31,368,500
- Market Cap $624M
- Description
- Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in precli...